Macro­Gen­ics gets $15M from Gilead; Zenas, Bris­tol My­ers sign li­cens­ing deal in Asia-Pa­cif­ic

Macro­Gen­ics is set to re­ceive a $15 mil­lion mile­stone pay­ment from Gilead, which is us­ing the com­pa­ny’s two bis­pe­cif­ic an­ti­body plat­forms in a re­search pro­gram. The pro­gram will be led by Macro­Gen­ics and fund­ed by Gilead.

The orig­i­nal part­ner­ship was struck in Oc­to­ber 2022. Macro­Gen­ics is still en­ti­tled to re­ceive up to $1.7 bil­lion from the deal. The part­ner­ship al­so cov­ers Macro­Gen­ics’ CD123- and CD3-tar­get­ing bis­pe­cif­ic an­ti­body MGD024 and two oth­er bis­pe­cif­ic re­search as­sets. — An­na Brown

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER